Squamous cell carcinoma of head and neck

• An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1) Pending
  2025-522944-41-00 7 "Solid Tumours"
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors Pending
  2025-523232-39-00 1 "Advanced Solid Tumors"
• DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Pending
  2025-523895-22-00 4 "Non-small cell lung cancer (NSCLC)"
• A phase III study on using immunotherapy and radiotherapy to treat limited spread of Head and Neck Cancer Recruiting
  2023-504478-39-00 5 2025-05-23
• A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications Recruiting
  2023-506227-29-00 3 2024-08-30 "locally advanced or metastatic solid tumors"
• VB10.16 Plus Pembrolizumab in First Line r/m HNSCC Recruiting
  2022-503055-26-00 9 2023-10-30 "Unresectable recurrent or metastatic HPV16 (Human Papilloma "
• A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC Recruiting
  2025-522914-22-00 3 2026-02-11 "Locally Advanced Head and Neck Squamous Cell Carcinoma (LA H"
• A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors Recruiting
  2025-521535-36-00 1 2025-11-03 "Locally advanced, metastatic NSCLC, CRC, or HNSCC that has r"
• A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors Recruiting
  2024-516870-31-00 1 2025-07-11 "Endometrial Carcinoma"
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 "Recurrent or Metastatic Solid Tumors (endometrial cancer (EC"
• A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and it … Recruiting
  2023-508126-95-00 1 2025-02-10 "The target population of the trial consists of patients with"
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 "Neoplasms, Head and Neck"
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 "Recurrent or metastatic head and neck squamous cell carcinom"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 "Advanced or metastatic solid tumors including hormone recept"
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 1 2024-02-14 "Triple negative breast cancer"
• A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advan … Recruiting
  2023-508227-13-00 7 2023-06-19 "Advanced solid tumors"
• A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli … Recruiting
  2024-512671-12-00 10 2021-03-05 "Unresectable head and neck squamous cell carcinoma, metastat"
• A phase I/II trial of TG4050, an individualised gene therapy, in patients with advanced cancer of the head and neck. Recruiting
  2023-508561-33-00 7 2019-12-12 "Newly diagnosed, stage III or IV amenable to surgery, HPV ne"
• Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Recruitment ended
  2024-515538-34-00 10 2025-02-27 "Head and Neck Squamous Cell Carcinoma"
• A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced … Recruitment ended
  2022-502381-25-01 1 2024-03-15 "Thymic Carcinoma"
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Recruitment ended
  2023-503428-24-00 4 2024-01-19 "Neoplasms, Head and Neck"
• Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head a … Recruitment ended
  2024-516779-33-00 9 2023-11-08 "Carcinoma"
• Phase I study of AZD9592 in solid tumors Recruitment ended
  2022-501570-18-00 1 2023-07-18 "Recurrent or metastatic Head and NeckSquamous Cell Carcinoma"
• An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu … Recruitment ended
  2023-506184-34-00 5 2019-08-09 "Advanced Malignancies"

Showing 1–24 of 48 trials